Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 6:44 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 1,257 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Local Disease Clear all

Conditions: Spinal Cord Injuries, Nerve Injury, Pain, Postoperative, Post Herpetic Neuralgia, Complex Regional Pain Syndromes, Post-Stroke Pain, Post Radiation Brain Injury, Post Radiation Plexopathy, Nerve Root Avulsion
Interventions: Medtronic Summit RC+S or Percept RC; Device
Lead sponsor: University of California, San Francisco; Other
Eligibility: 22 Years to 80 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2030
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Anesthesia, Local, Pain
Interventions: 1% Buffered Lidocaine 1:100,000 Epinephrine, 2% Unbuffered Lidocaine 1:100,000 Epinephrine; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 10 Years to 12 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Complex Regional Pain Syndrome Type I
Interventions: Neridronate; Drug
Lead sponsor: Ambros Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Selpercatinib, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 15
States / cities: Los Angeles, California • Stockton, California • Torrance, California + 11 more

Conditions: Gastrin-Producing Neuroendocrine Tumor, Lung Carcinoid Tumor, Metastatic Digestive System Neuroendocrine Tumor G1, Multiple Endocrine Neoplasia Type 1, Pancreatic Glucagonoma, Pancreatic Insulinoma, Pancreatic Polypeptide Tumor, Recurrent Digestive System Neuroendocrine Tumor G1, Recurrent Pancreatic Neuroendocrine Carcinoma, Regional Digestive System Neuroendocrine Tumor G1, Somatostatin-Producing Neuroendocrine Tumor
Interventions: Laboratory Biomarker Analysis, Pazopanib Hydrochloride, Pharmacological Study; Other · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 21 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 3
States / cities: Boston, Massachusetts • Houston, Texas

Conditions: Prostatic Neoplasms, Prostate Neoplasms, Prostate Cancer
Interventions: 5-Azacitidine, all trans retinoic acid, Lupron; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older · Male only
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Bladder Cancer
Interventions: BCG strain of Mycobacterium bovis; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Onychomycosis
Interventions: EcoNail™ (econazole 5%/SEPA® 18% nail lacquer); Drug
Lead sponsor: Abeona Therapeutics, Inc; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 3
States / cities: Tucson, Arizona • New York, New York • Portland, Oregon

Conditions: Complex Regional Pain Syndrome (CRPS)
Interventions: Neridronic acid 100 mg, Placebo; Drug
Lead sponsor: Grünenthal GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 182 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 39
States / cities: Huntsville, Alabama • Mobile, Alabama • Peoria, Arizona + 35 more

Conditions: Regional Anesthesia, Horner Syndrome, Cerebral Blood Flow
Interventions: TCD Measurement; Device
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Stanford, California

Conditions: Lymphoma, Non-Hodgkin, Lymphoma, Lymphomas: Non-Hodgkin Follicular / Indolent B-Cell, Lymphomas: Non-Hodgkin
Interventions: PF-3512676, Local radiotherapy; Drug · Radiation
Lead sponsor: Ronald Levy; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Stanford, California

Conditions: Breast Cancer, Breast Neoplasm, Breast Tumor, Cancer of the Breast
Interventions: Proton Radiotherapy; Radiation
Lead sponsor: Proton Collaborative Group; Network
Eligibility: 18 Years and older
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2032
U.S. locations: 5
States / cities: Warrenville, Illinois • Baltimore, Maryland • Somerset, New Jersey + 2 more

Conditions: Hemophilia, Hemorrhage, Facelift Surgery
Interventions: 1%Tranexamic acid with standard local, 3% TXA, 1% TXA with local plus 3% TXA-soaked pledgets; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Anesthetic Effectiveness
Interventions: Articaine Hydrochloride + Epinephrine, Buffered Articaine Hydrochloride + Epinephrine; Drug
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Constrictive Bronchiolitis, Iraq-Afganistan War Lung Injury Syndrome
Interventions: Perfluorinated Gas/Oxygen Mixture; Diagnostic Test
Lead sponsor: Hal C Charles; Other
Eligibility: 18 Years to 99 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Diabetes Mellitus, Type 2
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 50 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 1999 – 2005
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Oropharyngeal Cancer, HPV-Related Squamous Cell Carcinoma
Interventions: Gabapentin; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Gout, Hyperuricemia, Gout Flare, Tophi
Interventions: Tigulixostat, Allopurinol, Placebo; Drug
Lead sponsor: LG Chem; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 2,202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 124
States / cities: Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 91 more

Conditions: Extensive Stage Small Cell Lung Cancer, Hereditary Paraganglioma, Male Breast Cancer, Malignant Paraganglioma, Metastatic Gastrointestinal Carcinoid Tumor, Metastatic Pheochromocytoma, Pancreatic Polypeptide Tumor, Recurrent Breast Cancer, Recurrent Cervical Cancer, Recurrent Endometrial Carcinoma, Recurrent Gastrointestinal Carcinoid Tumor, Recurrent Islet Cell Carcinoma, Recurrent Neuroendocrine Carcinoma of the Skin, Recurrent Non-small Cell Lung Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Recurrent Pheochromocytoma, Recurrent Prostate Cancer, Recurrent Renal Cell Cancer, Recurrent Small Cell Lung Cancer, Recurrent Uterine Sarcoma, Regional Gastrointestinal Carcinoid Tumor, Regional Pheochromocytoma, Stage III Cervical Cancer, Stage III Endometrial Carcinoma, Stage III Neuroendocrine Carcinoma of the Skin, Stage III Ovarian Epithelial Cancer, Stage III Ovarian Germ Cell Tumor, Stage III Prostate Cancer, Stage III Renal Cell Cancer, Stage III Uterine Sarcoma, Stage IIIA Breast Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Breast Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage IV Endometrial Carcinoma, Stage IV Neuroendocrine Carcinoma of the Skin, Stage IV Non-small Cell Lung Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Ovarian Germ Cell Tumor, Stage IV Prostate Cancer, Stage IV Renal Cell Cancer, Stage IV Uterine Sarcoma, Stage IVA Cervical Cancer, Stage IVB Cervical Cancer, Thyroid Gland Medullary Carcinoma
Interventions: temsirolimus, vinorelbine ditartrate; Drug
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Sarcoma,Soft Tissue
Interventions: 2% intranasal mupirocin ointment, 4% chlorhexidine gluconate body cleanser; Drug
Lead sponsor: Adam Olson; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Pain, Procedural Pain, Local Anesthesia, Mohs Surgery, Skin Cancer
Interventions: Active Vibration:TENS, Sham TENS; Device
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 3
States / cities: Maple Grove, Minnesota • Minneapolis, Minnesota • Wyoming, Minnesota

Conditions: Obesity, Overweight
Interventions: Whey Protein, Whey Protein and Resistance Exericse, Whey Protein and RISE exercise routine; Dietary Supplement · Other
Lead sponsor: Skidmore College; Other
Eligibility: 30 Years to 60 Years
Enrollment: 79 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Saratoga Springs, New York

Conditions: Rib Fractures
Interventions: hydromorphone hydrochloride, Infusion catheter placement, bupivicaine 0.25%, bupivicaine 0.5%; Drug · Procedure
Lead sponsor: Anthony Iacco; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 1
States / cities: Royal Oak, Michigan

Conditions: Pain, Acute, Anesthesia, Local, Dermatology/Skin - Other
Interventions: Vibratory Anesthetic Device (VAD); Device
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 101 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Search by objective public record fields.

Closed-Loop Deep Brain Stimulation for Refractory Chronic Pain

Clinical Trial Comparing Effectiveness of Buffered Versus Unbuffered Local Anesthetic in Children Ages 10-12 Years

Phase 3, Open-Label Extension Study of AMBTX-01 (Neridronate) for Complex Regional Pain Syndrome Type 1

A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)

Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer

A Pilot Study of 5-AZA and ATRA for Prostate Cancer With PSA-only Recurrence After Local Treatment

Intravesical BCG Administration to Patients With Invasive Bladder Cancer

A Trial of the Safety and Efficacy of EcoNail™ in the Treatment of Fungus Infections of the Great Toenail

Efficacy and Safety of Intravenous Neridronic Acid in CRPS

Cerebral Blood Flow Evaluation With Trancranial Doppler After Interscalene Nerve Block

A Phase 2 Intratumoral Injection PF-3512676 Plus Local Radiation in Low-Grade B-Cell Lymphomas

Proton Radiation for Stage II/III Breast Cancer

Topical and Local TXA in Facelifts - A Randomized Controlled Double Blinded Study

Testing the Anesthetic Effectiveness of Buffered Articaine Injected Next to a Lower First Molar.

Iraq- Afghanistan War Lung Injury Using 19F MRI (DIAL1001006)

Regional Fatty Acid Metabolism in Humans

PROGRESS Trial - Prophylactic Gabapentin for Relief of Symptoms and Improved Swallowing

Tigulixostat, Phase 3 Study, Allopurinol Controlled in Gout Patients

Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors

Bacterial Decolonization Plus Intraoperative Angiography for Soft Tissue Sarcomas Receiving Preoperative Radiotherapy (CONCERTO)

E-MOHS Trial of TENS and Vibration During Local Anesthesia

Whey Protein Intake With and Without Exercise on Visceral Fat: The P+RISE Study

Continuous Intercostal Nerve Blockade for Traumatic Rib Fractures

Variable Perception of Cutaneous Stimulation